Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. DOI:10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• [6th March 2022, 17:21]. Available from: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6.
   Google Scholar
• He J, Guo Y, Mao R, et al. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. J Med Virol. 2021;93:820–830.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–1720. DOI:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Chams N, Chams S, Badran R, et al. COVID-19: A Multidisciplinary Review. Front Public Health. 2020;8:383.
   PubMed Web of Science ®Google Scholar
• Tisoncik JR, Korth MJ, Simmons CP, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76:16–32.
   PubMed Web of Science ®Google Scholar
• Pouresmaieli M, Ekrami E, Akbari A, et al. A comprehensive review on efficient approaches for combating coronaviruses. Biomed Pharmacother. 2021;144:112353.
   PubMed Web of Science ®Google Scholar
• Update on Omicron 2021 [ Available from: https://www.who.int/news/item/28-11-2021-update-on-omicron
   Google Scholar
• What is MS? [ Available from: https://www.nationalmssociety.org/What-is-MS
   Google Scholar
• Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020;77:1079–1088. DOI:10.1001/jamaneurol.2020.2581
   PubMed Web of Science ®Google Scholar
• Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021;97:1870–1885. DOI:10.1212/WNL.0000000000012753
   PubMed Web of Science ®Google Scholar
• Sahraian MA, Azimi A, Navardi S, et al. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020;46:102472.
   PubMed Web of Science ®Google Scholar
• Mohn N, Konen FF, Pul R, et al. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. Clin Med. 2020;9:4067. DOI:10.3390/jcm9124067
   Web of Science ®Google Scholar
• Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021;89:780–789. DOI:10.1002/ana.26028
   PubMed Web of Science ®Google Scholar
• Sormani MP, Salvetti M, Labauge P, et al. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021;8:1738–1744.
   PubMed Web of Science ®Google Scholar
• Ciampi E, Uribe-San-Martin R, Soler B, et al. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile. Mult Scler Relat Disord. 2020;45:102392.
   PubMed Web of Science ®Google Scholar
• Moss BP, Mahajan KR, Bermel RA, et al. Multiple sclerosis management during the COVID-19 pandemic. Mult Scler. 2020;26:1163–1171.
   PubMed Web of Science ®Google Scholar
• Moreno-Torres I, Meca Lallana V, Costa-Frossard L, et al. Risk and outcomes of COVID-19 in patients with multiple sclerosis. Eur J Neurol. 2021;28:3712–3721.
   PubMedGoogle Scholar
• Chaudhry F, Bulka H, Rathnam AS, et al. COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020;418:117147.
   PubMed Web of Science ®Google Scholar
• Loonstra FC, Hoitsma E, van Kempen ZL, et al. COVID-19 in multiple sclerosis: The Dutch experience. Mult Scler. 2020;26:1256–1260.
   PubMedGoogle Scholar
• Solomon JM, Jones A, Hohol M, et al. Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada. Mult Scler Relat Disord. 2022;58:103509.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Tortorella C, Haggiag S, et al. Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies. J Neurol. 2022. DOI:10.1007/s00415-021-10951-6.
   Web of Science ®Google Scholar
• Perez CA, Zhang GQ, Li X, et al. COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study. Mult Scler Relat Disord. 2021;55:103217.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1105. DOI:10.1212/NXI.0000000000001105
   PubMed Web of Science ®Google Scholar
• Zabalza A, Arrambide G, Tagliani P, et al. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1143.
   PubMed Web of Science ®Google Scholar
• Iaffaldano P, Lucisano G, Manni A, et al. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1141.
   PubMed Web of Science ®Google Scholar
• Garjani A, Middleton RM, Nicholas R, et al. Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1118. DOI:10.1212/NXI.0000000000001118
   PubMed Web of Science ®Google Scholar
• Maury A, Lyoubi A, Peiffer-Smadja N, et al. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev Neurol (Paris). 2021;177:51–64.
   PubMed Web of Science ®Google Scholar
• Palao M, Fernandez-Diaz E, Gracia-Gil J, et al. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord. 2020;45:102377.
   PubMed Web of Science ®Google Scholar
• Zanin L, Saraceno G, Panciani PP, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 2020;162:1491–1494.
   PubMed Web of Science ®Google Scholar
• Pignolo A, Aprile M, Gagliardo C, et al. Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection. Neurol Int. 2021;13:695–700.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Sedaghat N, Aghababaee A, et al. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?. Mult Scler Relat Disord. 2021;51:102915.
   PubMed Web of Science ®Google Scholar
• Michelena G, Casas M, Eizaguirre MB, et al. inverted question mark Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis. Mult Scler Relat Disord. 2022;57:103368.
   PubMed Web of Science ®Google Scholar
• Barzegar M, Vaheb S, Mirmosayyeb O, et al. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. Mult Scler Relat Disord. 2021;52:102947.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Abhari AP, Nouri H, et al. Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study. BMC Neurol. 2022;22:64.
   PubMed Web of Science ®Google Scholar
• Laroni A, Uccelli A. CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. J Clin Med. 2020;9:1450.
   Web of Science ®Google Scholar
• Laroni A, Schiavetti I, Sormani MP, et al. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler. 2021;27:2126–2136. DOI:10.1177/1352458520971817
   PubMedGoogle Scholar
• Schoggins JW. Interferon-Stimulated Genes: What Do They All Do?. Annu Rev Virol. 2019;6:567–584.
   PubMed Web of Science ®Google Scholar
• Galbraith MD, Kinning KT, Sullivan KD, et al. Specialized interferon action in COVID-19. Proc Natl Acad Sci U S A. 2022;119:e211673011.
   Web of Science ®Google Scholar
• Galani IE, Rovina N, Lampropoulou V, et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol. 2021;22:32–40.
   PubMed Web of Science ®Google Scholar
• Reder AT, Centonze D, Naylor ML, et al. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021;35:317–330.
   PubMed Web of Science ®Google Scholar
• Centonze D, Rocca MA, Gasperini C, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol. 2021;268:3961–3968. DOI:10.1001/jamaneurol.2021.0688
   PubMed Web of Science ®Google Scholar
• Freedman MS, Jack D, Murgasova Z, et al. Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis. Mult Scler Relat Disord. 2021;56:103283.
   PubMed Web of Science ®Google Scholar
• Registry C. The COViMS Database Public Data Update. 2021
   Google Scholar
• Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105:967–976.
   PubMed Web of Science ®Google Scholar
• Gandoglia I, Ivaldi F, Laroni A, et al. Teriflunomide treatment reduces B cells in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2017;4:e403.
   PubMed Web of Science ®Google Scholar
• Coelho AR, Oliveira PJ. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection. Eur J Clin Invest. 2020;50:e13366.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann Neurol. 2010;67:452–461.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Smith JB, Li BH, et al. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021;8:938–943.
   PubMed Web of Science ®Google Scholar
• Spelman T, Forsberg L, McKay K, et al. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Mult Scler. 2021; 13524585211026272. DOI: 10.1177/13524585211026272.
   Google Scholar
• Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021;78:699–708.
   PubMed Web of Science ®Google Scholar
• Iyer RB, R S, JN M, et al. COVID-19 outcomes in persons with multiple sclerosis treated with rituximab. Mult Scler Relat Disord. 2022;57:103371.
   PubMed Web of Science ®Google Scholar
• Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195.
   PubMed Web of Science ®Google Scholar
• Czarnowska A, Brola W, Zajkowska O, et al. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience. Neurol Neurochir Pol. 2021;55:212–222.
   PubMed Web of Science ®Google Scholar
• Kovvuru S, Nalleballe K, Onteddu SR, et al. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. J Neurol Sci. 2021;420:117230.
   PubMed Web of Science ®Google Scholar
• Sen S, Karabudak R, Schiavetti I, et al. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?. Mult Scler Relat Disord. 2021;52:102968.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383:546–557.
   PubMed Web of Science ®Google Scholar
• Adamec I, Rogic D, Penz MG, et al. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. J Neuroimmunol. 2022;362:577788.
   PubMed Web of Science ®Google Scholar
• Cross AH, Delgado S, Habek M, et al. Outcomes of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab: Data from the ALITHIOS Study and Post-marketing Surveillance. Mult Scler. 2021;27:797–798. 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021) 2021.
   Google Scholar
• Sullivan R, Kilaru A, Hemmer B, et al. COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series. Neurol Neuroimmunol Neuroinflamm. 2021;9:e1092.
   PubMed Web of Science ®Google Scholar
• Walsh KB, Teijaro JR, Wilker PR, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108:12018–12023.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21:22–34.
   PubMed Web of Science ®Google Scholar
• COVID-19 Vaccine Guidance for People Living with MS [ Available from: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance
   Google Scholar
• Coyle PK, Gocke A, Vignos M, et al. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Adv Ther. 2021;38:3550–3588.
   PubMed Web of Science ®Google Scholar
• von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2018;5:e409.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020;95:e1999–e2008.
   PubMed Web of Science ®Google Scholar
• Kim W, Kim SH, Huh SY, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol. 2013;20:975–980.
   PubMed Web of Science ®Google Scholar
• Richi P, Alonso O, Martin MD, et al. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study. Clin Rheumatol. 2020;39:2751–2756.
   PubMed Web of Science ®Google Scholar
• Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler. 2021;27:864–870. DOI:10.1177/13524585211003476.
   PubMed Web of Science ®Google Scholar
• Dreyer-Alster S, Dolev M, Menascu, S, et al. COVID-19 vaccinations in patient with multiple sclerosis: what we have learnt by May 2021. Mult Scler. 2021;27:253–254. 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021) 2021.
   Google Scholar
• Di Filippo MCC, Malucchi S, Malucchi S, et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2021;93:448–450. DOI:10.1136/jnnp-2021-327200
   PubMed Web of Science ®Google Scholar
• Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835. DOI:10.1177/17562864211012835
   Web of Science ®Google Scholar
• Achiron A Treatments in the context of MS: about DMT’s and SARS-CoV-2. Mult Scler. 2021;27(2S): 3–4.
   Google Scholar
• Apostolidis SA, Painter MM, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27:1990–2001. DOI:10.1038/s41591-021-01507-2
   PubMed Web of Science ®Google Scholar
• Tortorella C, Aiello A, Gasperini C, et al., Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. Neurology. 2021;98(5):e541–4. DOI:10.1212/WNL.0000000000013108.
   PubMed Web of Science ®Google Scholar
• Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 Vaccine Response in People with Multiple Sclerosis. Ann Neurol. 2022;91:89–100.
   PubMed Web of Science ®Google Scholar
• Brill L, Rechtman A, Zveik O, et al. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 2021;78:1510–1514. DOI:10.1001/jamaneurol.2021.3599
   PubMed Web of Science ®Google Scholar
• Iannetta M, Landi D, Cola G, et al. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. Front Immunol. 2021;12:796482.
   PubMedGoogle Scholar
• Ciampi E, Uribe-San-Martin R, Soler B, et al. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Mult Scler Relat Disord. 2022;59:103690.
   PubMed Web of Science ®Google Scholar
• Konig M, Torgauten HM, Tran TT, et al. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. JAMA Neurol. 2022;79:307–309.
   PubMed Web of Science ®Google Scholar
• COVID-19 Vaccines for Children and Adolescents with MS and Related Disorders [ Available from: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/COVID-19-Vaccines-for-Youth-with-MS
   Google Scholar
• Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Eur J Neurol. 2022;29:555–563.
   PubMed Web of Science ®Google Scholar
• Ismail SS II, Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2022;362:577765.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Abhari AP, Nouri H, et al. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. Hum Vaccin Immunother. 2022;18(1):e2041945.
   PubMed Web of Science ®Google Scholar
• Conte WL. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study. Mult Scler Relat Disord. 2022;57:103413.
   PubMed Web of Science ®Google Scholar
• Dreyer-Alster S, Menascu S, Mandel M, et al. COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose. J Neurol Sci. 2022;434:120155.
   PubMed Web of Science ®Google Scholar
• Moser T, Otto F, O’Sullivan C, et al. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study. Mult Scler Relat Disord. 2022;59:103560.
   PubMed Web of Science ®Google Scholar
• Ozakbas S, Baba C, Dogan Y, et al. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Mult Scler Relat Disord. 2022;58:103486.
   PubMed Web of Science ®Google Scholar
• Rose DR, Mahadeen AZ, Carlson AK, et al. Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7:20552173211057110.
   Google Scholar
• Sun J, Zheng Q, Madhira V, et al. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Intern Med. 2022;182:153–162.
   PubMed Web of Science ®Google Scholar
• Garjani A, Patel S, Bharkhada D, et al. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Mult Scler Relat Disord. 2022;57:103458.
   PubMed Web of Science ®Google Scholar
• Kataria S, Tandon M, Melnic V, et al. A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies. eNeurologicalSci. 2020;21:100287.
   PubMedGoogle Scholar
• Omicron makes up 95% of sequenced Covid cases in U.S. as infections hit pandemic record 2022 [ updated 4th January 2022. Available from: https://www.cnbc.com/2022/01/04/omicron-makes-up-95percent-of-sequenced-covid-cases-in-us-as-infections-hit-pandemic-record.html
   Google Scholar
• Jennings G, Monaghan A, Xue F, et al. A Systematic Review of Persistent Symptoms and Residual Abnormal Functioning following Acute COVID-19: Ongoing Symptomatic Phase vs. Post-COVID-19 Syndrome. J Clin Med. 2021;10:5913.
   PubMed Web of Science ®Google Scholar
• Weber MS, Nicholas JA, Yeaman MR. Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1067.
   PubMed Web of Science ®Google Scholar